drugset / Trial / NCT05417932
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
Timeline
- Start
- 2022-10-26
- Primary completion
- 2025-09
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCG101 | Cell therapy | — | — |